Protein expression and gene copy number analysis of topoisomerase 2α, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder - A multitissue array study with prognostic implications

Anticancer Research

Volumn 25, Issue 1 A, 2005, Pages 263-271

  Krüger, Stefan ^a   Lange, Irina ^a   Kausch, Ingo ^a   Feller, Alfred C ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Bladder carcinoma; FISH; HER2; Multitissue array; P53; Prognosis; Topoisomerase 2

Indexed keywords

BCG VACCINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTITISSUE ARRAY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSURETHRAL RESECTION; TREATMENT OUTCOME; UROGENITAL TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 16344385834     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Malmström P, Busch C and Norlen BJ: Recurrence, progression and survival in bladder cancer: a retrospective analysis of 232 patients with ≥5-year follow-up. Scand J Urol Nephrol 21: 185-195, 1987.
2. Holmäng S, Hedelin H, Anderström C and Johansson SL: The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell carcinoma of the bladder followed for at least 20 years. J Urol 153: 1823-1827, 1995.
3. Stein JP, Grossfeld GD, Ginsberg DA, Esrig D, Freeman JA, Figueroa AJ, Skinner DG and Cote RJ: Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 160: 645-659, 1998.
4. Cheng L, Neumann RM, Weaver AL, Spotts BE and Bostwick DG: Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 17: 3182-3187, 1999.
5. Sobin LH and Wittekind C: TNM Classification of Malignant Tumours, 6 ed. Indianapolis, Wiley 2002, pp. 187-189.
6. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Smeets AW and Pauwels RP: MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors. Cancer 88: 2598-2605, 2000.
7. deVere-White RW, Deitch AD, Daneshmand S, Blumenstein B, Lowe BA, Sagalowsky AI, Smith Jr JA, Schellhammer PF, Stanisic TH, Grossman HB, Messing E, Crissman JD and Crawford ED: The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer. A Southwest Oncology Group Study. Eur Urol 37: 595-600, 2000.
8. Mizutani Y, Wada H, Ogawa O, Yoshida O, Fukushima M, Nonomura N and Miki T: Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer 92: 510-518, 2001.
9. Popov Z, Hoznek A, Colombel M, Bastuji-Garin S, Lefrere-Belda MA, Bellot J, Abboh CC, Mazerolles C and Chopin DK: The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer 80: 1472-1481, 1997.
10. Gontero P, Casetta G, Zitella A, Ballario R, Paccioni D, Magnani C, Muir GH and Tizzani A: Evaluation of p53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. Eur Urol 38: 287-296, 2000.
11. Wu TT, Chen JH, Lee YH and Huang JK: The role of bcl-2, p53, and Ki-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J Urol 163: 758-760, 2000.
12. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, Carrasco JC, Requena MJ and Montironi R: Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21waf1, p27kip1, cyclin D1, and cyclin D3) and proliferation index (ki67-MIB1). Eur Urol 45: 606-612, 2004.
13. Kuczyk MA, Serth J, Bokemeyer C, Hervatin C, Oelke M, Oelert F, Hofner K and Jonas U: Value of the proliferation status (PCNA) and p53 immunohistochemistry as a prognostic factor for the clinical course of superficial cancer of the urinary bladder. Urologe A 34: 146-152, 1995.
14. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, Shirakawa H, Ishibe T and Kawanishi M: Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and DNA content in transitional cell carcinoma of the bladder. Cancer 78: 1762-1774, 1996.
15. Kamai T, Takagi K, Asami H, Ito Y, Oshima H and Yoshida KI: Decreasing of p27 (Kip1) and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 84: 1242-1251, 2001.
16. Tut VM, Braithwaite KL, Angus B, Neal DE, Lunec J and Mellon JK: Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with waf1, pRb and Ki67. Br J Cancer 84: 270-275, 2001.
17. Sgambato A, Migaldi M, Faraglia B, De Aloysio G, Ferrari P, Ardito R, De Gaetani C, Capelli G, Cittadini A and Trentini GP: Cyclin D1 expression in papillary superficial bladder cancer: its association with other cell cycle-associated proteins, cell proliferation and clinical outcome. Int J Cancer 97: 671-678, 2002.
18. Leissner J, Hohenfellner R, Thüroff JW, Koppen C and Wolf HK: Prognostic significance of histopathological grading and immunoreactivity for p53 and p21/WAF1 in grade 2 pTa transitional cell carcinoma of the urinary bladder. Eur Urol 39: 438-445, 2001.
19. Sgambato A, Migali M, Faraglia B, Garagnani L, Romano G, De Gaetani C, Ferrari P, Capelli G, Trentini GP and Cittadini A: Loss of P27Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 59: 3245-3250, 1999.
20. Nakopoulou L, Zervas A, Lazaris AC, Constantinides C, Stravodimos C, Davaris P and Dimopoulos C: Predictive value of topoisomerase 2α immunostaining in urothelial bladder carcinoma. J Clin Pathol 43: 309-313, 2001.
21. Raitanen MP, Tammela TL, Kallioniemi M and Isola J: p53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. J Urol 157: 1250-1253, 1997.
22. Bernardini S, Billerey C, Martin M, Adessi GL, Wallerand and Bittard H: The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J Urol 165: 42-46, 2001.
23. Serio G: C-erbB-2 gene product-like expression in urothelial carcinomas of the human bladder. Its value as a prognostic indicator in superficial tumors. Pathologica 83: 413-420, 1991.
24. Järvinen TA, Tanner M, Rantanen V, Bärlund M, Borg A, Grenman S and Isola J: Amplification and deletion of topoisomerase II-alpha associates with erbB-2 amplification and affects sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 156: 839-847, 2000.
25. Simon R, Atefy R, Wagner U, Forster T, Fijan A, Bruderer J, Wilber K, Mihatsch MJ, Gasser T and Sauter G: HER-2 and TOP2A amplification in urinary bladder cancer. Verh Dtsch Ges Path 56: 176-183, 2002.
26. Mahdy E, Pan Y, Wang N, Malmström PU, Ekman P and Bergerheim U: Chromosome 8 numerical aberration and C-MYC copy number gain in bladder cancer are linked to stage HI and grade. Anticancer Res 21: 3167-3173, 2001.
27. Nocito A, Bubendorf L, Maria-Tinner E, Suess K, Wagner U, Forster T, Kononen J, Fijan A, Bruderer J, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Anabitarte M, Hering F, Hardmeier T, Schoenenberger AJ, Flury R, Jäger P, Luc Fehr J, Schraml P, Moch H, Mihatsch MJ, Gasser T and Sauter G: Microarrays of bladder cancer tissue are highly representative of proliferation index and histologic grade. J Pathol 194: 349-357, 2001.
28. Mostofi F, Sobin LH and Torloni H: Histological typing of urinary bladder tumours. In: International Histological Classification of Tumours, No. 10. Geneva, WHO 1973, pp 17-17.
29. Stocker W, Teegen B, Meyer W, Müller-Kunert E, Proost S, Schlumberger W and Sonnenberg K: Differenzierte Autoantikörper-Diagnostik mit Biochip-Mosaiken. In: Autoantikörper (Conrad K, ed). Lengerich, Pabst 1998, pp 78-99.
30. Sauter G, Moch H, Gasser TC, Mihatsch MJ and Waldman FM: Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry 21: 40-46, 1995.
31. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga MLTH, Seymour GJ and Lavin MF: Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 73: 526-532, 1994.
32. Nakopoulou L, Constantinides C, Papandropoulos J, Theodoropoulos G, Tzonou A, Giannopoulos A, Zervas A and Dimopoulos C: Evaluation of over-expression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 46: 334-340, 1995.
33. Vatne V, Maartmannmoe H and Hoestmark J: The prognostic value of p53 in superficially infiltrating transitional cell carcinoma. Scand J Urol Nephrol 29: 491-495, 1995.
34. Underwood MA, Reeves J, Smith G, Gardiner DS, Scott R, Bartlett J and Cooke TG: Overexpression of p53 protein and its significance for recurrent progressive bladder tumours. Br J Urol 77: 659-666, 1996.
35. Korkolopoulou P, Christodoulou P, Kapralos P, Exarchakos M, Bisbiroula A, Hadjiyannakis M, Georgountzos C and Thomas-Tsagli E: The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol Res Pract 193: 767-775, 1997.
36. Lipponen P: Expression of c-erbB-2 oncoprotein in transitional cell bladder cancer. Eur J Cancer 29: 749-753, 1993.
37. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P and Neal DE: C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 155: 321-326, 1996.
38. Ravery V, Grignon D, Angulo J, Pontes E, Montie J, Crissman J and Chopin D: Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol Res 25: 9-17, 1997.
39. Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC and Bohle A: Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21: 981-987, 2002.
40. Schraml P, Jononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP and Sauter G: Tissue microarrays for gene amplification surveys in many different tumor types. Clin Cancer Res 5: 1966-1975, 1999.
41. Latif Z, Watters AD, Dunn I, Grigor KM, Underwood MA and Bartlett JMS: HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer 89: 1305-1309, 2003.
42. Ohashi Y, Sasano H, Yamaki H, Shizawa S, Kikuchi A, Shimeha R, Akaichi T, Satomi S and Nagura H: Topoisomerase IIα expression in squamous cell carcinoma. Anticancer Res 19: 1873-1880, 1999.
43. Depowski PL, Rosenthal SI, Brien TP, Stylos S, Johnson RL and Ross JS: Topoisomerase IIα expression in breast cancer: correlation with outcome variables. Mod Pathol 13: 542-547, 2000.
44. Smits G, Schaafsma E, Kiemeney L, Caris C, Debruyne F and Witjes JA: Microstaging of pT1 transitional cell carcinoma of the bladder: identification of subgroups with distinct risks of progression. Urology 52: 1009-1013, 1998.
45. Platz CE, Cohen MB, Jones MP, Olsen DB and Lynch CF: Is microstaging of early invasive cancer of the urinary bladder possible or useful? Mod Pathol 11: 1035-1039, 1996.
46. Weizer A, Green A, Shaw C, Wheeler T and Lerner S: Risk assessment of T1 transitional cell carcinoma of the bladder using p53 immunohistochemistry and pathologic substaging. J Urol 161(Suppl): 315A, 1999.